Research ExplorerPublicationsHealth-related quality of life in the ENDEAVOR study: carfil...

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Standard

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. / Ludwig, Heinz; Moreau, Philippe; Dimopoulos, Meletios A; Mateos, Maria-Victoria; Kaiser, Martin; Hajek, Roman; Feng, Shibao; Cocks, Kim; Buchanan, Jaqueline; Weisel, Katja.

In: BLOOD CANCER J, Vol. 9, No. 3, 22.02.2019, p. 23.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ludwig, H, Moreau, P, Dimopoulos, MA, Mateos, M-V, Kaiser, M, Hajek, R, Feng, S, Cocks, K, Buchanan, J & Weisel, K 2019, 'Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma', BLOOD CANCER J, vol. 9, no. 3, pp. 23. https://doi.org/10.1038/s41408-019-0181-0

APA

Ludwig, H., Moreau, P., Dimopoulos, M. A., Mateos, M-V., Kaiser, M., Hajek, R., Feng, S., Cocks, K., Buchanan, J., & Weisel, K. (2019). Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. BLOOD CANCER J, 9(3), 23. https://doi.org/10.1038/s41408-019-0181-0

Vancouver

Ludwig H, Moreau P, Dimopoulos MA, Mateos M-V, Kaiser M, Hajek R et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. BLOOD CANCER J. 2019 Feb 22;9(3):23. https://doi.org/10.1038/s41408-019-0181-0

Bibtex

@article{fddf2a0cc5f1442f8bb1b8a054c58902,
title = "Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma",
abstract = "We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire (QLQ-C30), MM-specific module (QLQ-MY20), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) {"}Additional Concerns{"} neurotoxicity subscale. The QLQ-C30 Global Health Status (GHS)/QoL scale and seven prespecified subscales were compared between groups using mixed model for repeated measures. Of 929 randomized patients, 911 with ≥1 post-baseline assessment were included. Kd56 was associated with statistically significant improvements in GHS/QoL, fatigue, pain, side effects, and FACT/GOG-Ntx scores versus Vd, although mean differences did not meet thresholds for clinical significance. The Kd56 group had longer time to deterioration (TTD) in GHS/QoL (median 3.7 versus 2.8 months, p = 0.0046), physical function (5.6 versus 3.7 months, p = 0.0390), nausea/vomiting (17.6 versus 8.2 months, p = 0.0358), side effects (6.4 versus 3.7 months p < 0.0001), and FACT/GOG-Ntx (11.1 versus 5.5 months, p = 0.0004). Overall, Kd56 resulted in statistically but not clinically significant improvements in mean GHS/QoL scores versus Vd. Treatment with Kd56 versus Vd also significantly prolonged TTD in GHS/QoL, physical function, nausea/vomiting, side effects, and FACT/GOG-Ntx.",
keywords = "Journal Article",
author = "Heinz Ludwig and Philippe Moreau and Dimopoulos, {Meletios A} and Maria-Victoria Mateos and Martin Kaiser and Roman Hajek and Shibao Feng and Kim Cocks and Jaqueline Buchanan and Katja Weisel",
year = "2019",
month = feb,
day = "22",
doi = "10.1038/s41408-019-0181-0",
language = "English",
volume = "9",
pages = "23",
journal = "BLOOD CANCER J",
issn = "2044-5385",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

AU - Ludwig, Heinz

AU - Moreau, Philippe

AU - Dimopoulos, Meletios A

AU - Mateos, Maria-Victoria

AU - Kaiser, Martin

AU - Hajek, Roman

AU - Feng, Shibao

AU - Cocks, Kim

AU - Buchanan, Jaqueline

AU - Weisel, Katja

PY - 2019/2/22

Y1 - 2019/2/22

N2 - We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire (QLQ-C30), MM-specific module (QLQ-MY20), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) "Additional Concerns" neurotoxicity subscale. The QLQ-C30 Global Health Status (GHS)/QoL scale and seven prespecified subscales were compared between groups using mixed model for repeated measures. Of 929 randomized patients, 911 with ≥1 post-baseline assessment were included. Kd56 was associated with statistically significant improvements in GHS/QoL, fatigue, pain, side effects, and FACT/GOG-Ntx scores versus Vd, although mean differences did not meet thresholds for clinical significance. The Kd56 group had longer time to deterioration (TTD) in GHS/QoL (median 3.7 versus 2.8 months, p = 0.0046), physical function (5.6 versus 3.7 months, p = 0.0390), nausea/vomiting (17.6 versus 8.2 months, p = 0.0358), side effects (6.4 versus 3.7 months p < 0.0001), and FACT/GOG-Ntx (11.1 versus 5.5 months, p = 0.0004). Overall, Kd56 resulted in statistically but not clinically significant improvements in mean GHS/QoL scores versus Vd. Treatment with Kd56 versus Vd also significantly prolonged TTD in GHS/QoL, physical function, nausea/vomiting, side effects, and FACT/GOG-Ntx.

AB - We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire (QLQ-C30), MM-specific module (QLQ-MY20), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) "Additional Concerns" neurotoxicity subscale. The QLQ-C30 Global Health Status (GHS)/QoL scale and seven prespecified subscales were compared between groups using mixed model for repeated measures. Of 929 randomized patients, 911 with ≥1 post-baseline assessment were included. Kd56 was associated with statistically significant improvements in GHS/QoL, fatigue, pain, side effects, and FACT/GOG-Ntx scores versus Vd, although mean differences did not meet thresholds for clinical significance. The Kd56 group had longer time to deterioration (TTD) in GHS/QoL (median 3.7 versus 2.8 months, p = 0.0046), physical function (5.6 versus 3.7 months, p = 0.0390), nausea/vomiting (17.6 versus 8.2 months, p = 0.0358), side effects (6.4 versus 3.7 months p < 0.0001), and FACT/GOG-Ntx (11.1 versus 5.5 months, p = 0.0004). Overall, Kd56 resulted in statistically but not clinically significant improvements in mean GHS/QoL scores versus Vd. Treatment with Kd56 versus Vd also significantly prolonged TTD in GHS/QoL, physical function, nausea/vomiting, side effects, and FACT/GOG-Ntx.

KW - Journal Article

U2 - 10.1038/s41408-019-0181-0

DO - 10.1038/s41408-019-0181-0

M3 - SCORING: Journal article

C2 - 30796199

VL - 9

SP - 23

JO - BLOOD CANCER J

JF - BLOOD CANCER J

SN - 2044-5385

IS - 3

ER -